Los Angeles Allergist

Los Angeles Allergist

Alan Khadavi, MD, APC
  • Home
  • Meet Dr. Khadavi
  • Conditions We Treat
  • Your First Visit
  • Insurance Accepted
  • Allergy and Asthma Info
    • Asthma Info
    • Allergic Rhinitis
    • Allergic Triggers
  • Blog
  • Media
  • Contact Us

9001 Wilshire Blvd. Suite 204
Beverly Hills, CA 90211
Phone: 310-282-8822

15450 Ventura Blvd. Suite 102
Sherman Oaks, CA 91403
Phone: 818-528-7776

November 17, 2019 by Alan Khadavi

Etokimab, anti IL-33 for Food Allergy

Etokimab is an antibody that inhibits IL-33.  IL-33 is a pro-inflammatory cytokine that is a central mediator of allergy diseases (i.e. food allergies).  By blocking IL-33, etokimab prevents the downstream inflammation that occurs with allergy diseases.

Etokimab is currently being studied for the treatment of atopic dermatitis and asthma by the pharmaceutical company AnaptysBio.

The results of the trial for eczema and asthma have been disappointing to date, but a recent small study explored Etokimab’s role in the treatment of food allergy, in this case peanut allergy.  A study was done with participants who had peanut allergy and they received an injection of Etokimab.  Nearly 3/4 of participants who received the injection were able to eat a modest amount of peanut 2 weeks after the shot. Zero of the patients who received a placebo were able to eat peanut.  Since Etokimab doesn’t particularly treat peanut specifically but overall allergies, there is a potential it could treat any food allergies such as tree nuts and shellfish.

This was a very small study and more studies need to be done. It still has not been determined at what frequency Etokimab would need to be given to protect against food allergies although researchers have been looking at a monthly treatment.  This most likely would be more used for accidental exposures and not for patients looking to eat a particular food allergen ad lib.

Approximately 32 million Americans suffer from food allergies and there are approximately 200,000 ER visits a year for this issue. There are a multitude of other treatments that are being investigated for peanut allergy.  There is the oral immunotherapy, Palforzia, a peanut patch is also being developed too.

Palforzia (formerly AR101) and peanut allergy

Prevention is the most important key to avoid peanut allergy, current guidelines support the early introduction of peanuts in babies.

New Peanut Guidelines

Caregivers are not supporting early peanut introduction guidelines

AR101 a Potential Peanut Allergy Cure

Peanut Allergy Cure?

Peanut Allergy Prevention

 

 

 

Filed Under: biologics, Blog, Food allergy

alan-khadavi
Dr. Alan Khadavi
Allergy & Asthma Specialist

Latest Posts

November 17, 2026

Low Dose Naltrexone for MCAS: Benefits, Risks, and Evidence

LDN for MCAS

November 13, 2026

Cardamom Allergy: Symptoms, Diagnosis, and What to Avoid

cardamom allergy

October 28, 2026

Dr. Alan Khadavi Recognized as Top Allergist in Southern California

Dr. Alan Khadavi Recognized as Top Allergist in Southern California

October 26, 2026

Which Biologic Works Best for Nasal Polyps?

best biologic for nasal polyps

October 19, 2026

Xolair vs. Omlyclo: Cost, Effectiveness, Insurance & Switching

Xolair vs Omlyclo: Cost, Effectiveness, Insurance & Switching

October 8, 2026

Tapioca Allergy: Can Cassava Cause an Allergic Reaction?

tapioca allergy

October 8, 2026

Rhapsido for Symptomatic Dermographism: An Allergist Explains the New FDA-Approved Treatment

Rhapsido for symptomatic dermographism

October 6, 2026

Most Effective Treatments for Severe Atopic Dermatitis: New Rankings

`most-effective-treatments-severe-atopic-dermatitis

October 6, 2026

Should Airlines Be Required to Carry Epinephrine? An Allergist Explains

airline epinephrine requirement

October 2, 2026

Ketotifen for MCAS: Uses, Benefits, Side Effects, and U.S. Availability

ketotifen for MCAS

Read More Posts...

Follow Us…

© 2026 Allergy Los Angeles. All Rights Reserved · Log in · Return to top of page